United Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,646,200.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, January 13th. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $939,625.74. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00.
• On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $407.32, for a total transaction of $6,109,800.00.
• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $1.82 during trading hours on Tuesday, hitting $364.70. 294,949 shares of the stock were exchanged, compared to its average volume of 258,869. The company has a market cap of $16.28 billion, a PE ratio of 16.02, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57. The company’s fifty day simple moving average is $370.22 and its two-hundred day simple moving average is $352.98. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the previous year, the business earned $5.38 EPS. The firm’s revenue was up 22.9% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. USA Financial Formulas purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at about $33,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics during the third quarter valued at approximately $82,000. Values First Advisors Inc. purchased a new position in United Therapeutics during the third quarter valued at $90,000. Finally, Benjamin F. Edwards & Company Inc. raised its stake in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 42 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on UTHR. LADENBURG THALM/SH SH boosted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, TD Cowen lifted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.